Panbela Announces Issuance Of New Patent In Japan; Patent Is For Claims Of A Novel Process For The Production Of SBP-101
Panbela Announces Issuance Of New Patent In Japan; Patent Is For Claims Of A Novel Process For The Production Of SBP-101
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for patent JP 7232845 titled "METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL". This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid till 2039.
潘貝拉治療學, 公司. (NASDAQ: PBLA) 是一家臨床階段生物製藥公司，開發用於治療癌症患者的破壞性療法，今天宣布發出一份專利發出通知，標題為「生產方法（6S,15S）-3,8,13,18-TETRAAZAICOSANE-6 ,15-DIOL」。該專利與綜合研究、開發和製造服務公司 Syngene International Ltd. 合作開發，宣稱一種新穎的工藝，將合成步驟從 17 個減少到六個，以生產主要研究產品 SBP-101。該專利的有效期至 2039 年。
Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutics, commented, "We're excited to have this patent in Japan. Expansion of our patent portfolio further supports our global clinical programs. This patent is the outcome of the dedicated efforts of our valued long-term partner Syngene International Ltd. in helping us achieve this important goal." First issued in the United States in 2021, this patent covers a shorter synthesis of SBP-101, which provides many benefits including: 1) the ability to manufacture product with a reduced lead time 2) quicker access to drug supply facilitating expansion into additional indications and 3) enables a scalable, efficient and cost-effective manufacturing process for future commercialization.
潘貝拉治療學總裁兼首席執行官 MSN 博士珍妮佛·辛普森評論說：「我們很高興能在日本獲得這項專利。擴大我們的專利組合進一步支持我們的全球臨床計劃。這項專利是我們寶貴的長期合作夥伴 Syngene 國際有限公司致力於幫助我們實現這一重要目標的成果。」該專利於 2021 年在美國首次發行，涵蓋了 SBP-101 的合成更短，其中提供了許多好處，包括：1）製造產品的能力，並縮短交貨時間 2）更快獲得藥物供應，促進擴展到其他適應症，以及 3）為未來的商業化提供可擴展，高效和經濟高效的製造過程。
Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Ltd., said, "We have been partnering with Panbela for the last decade, and I am proud of the work achieved through the successful collaboration. In this case, reducing the number of steps in production and simplifying the manufacturing process means that the drug will reach patients faster. The protection of SBP-101 production through patents in the U.S. and now in Japan are significant milestones."
Syngene 國際有限公司董事總經理兼首席執行官 Jonathan Hunt 表示：「過去十年來，我們一直與 Panbela 合作，我為通過成功的合作所取得的工作感到自豪。在這種情況下，減少生產中的步驟數量和簡化製造過程意味著該藥物將更快地到達患者。通過在美國和現在在日本的專利保護 SBP-101 生產是重要的里程碑。」
Dr. Simpson added, "The Company expects to continue innovation and patent portfolio building to support our clinical programs. This process in this patent utilizes a pharmaceutical starting material that is widely available, increasing the availability of drug supply moving forward. "
Simpson 博士補充道：「該公司希望繼續創新和專利組合建設，以支持我們的臨床計劃。該專利中的此過程利用了廣泛可用的製藥起始材料，從而提高藥物供應的可用性向前邁進。「
譯文內容由第三人軟體翻譯。